Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives
- 1Department of Oncology, Changhai Hospital, Naval Medical University , ,
Abstract
Malignant ascites is a common, severe complication of advanced solid tumors, driven by multifactorial pathogenesis, including impaired lymphatic drainage, vascular endothelial growth factor-induced vascular hyperpermeability, pro-permeability inflammatory cytokines, and profound peritoneal immunosuppression. Clinically, it correlates with poor prognosis, reduced overall survival, and substantial quality-of-life deterioration. Current treatment remains predominantly palliative: repeated large-volume paracentesis offers transient symptom relief, fails to prevent reaccumulation, and carries procedural risks. Emerging evidence indicates malignant ascites is not merely passive fluid accumulation but an active, immunosuppressive niche shaped by bidirectional crosstalk among tumor cells, stromal components, diverse immune subsets (e.g., regulatory T cells, myeloid-derived suppressor cells, dysfunctional CD8 ⁺ T cells), and soluble mediators. This narrative review summarizes recent advances in immunomodulatory treatment for malignant ascites, with an emphasis on strategies targeting the ascitic immune microenvironment. Intraperitoneal administration of immune checkpoint inhibitors has shown acceptable safety and preliminary activity in early-phase single-arm trials, although confirmatory data from larger controlled studies are lacking. In randomized trials, the T-cell engager catumaxomab prolonged puncture-free survival, while the bispecific antibody M701 has shown similar benefits in a phase II randomized controlled study; these findings support further investigation of localized T-cell redirection. Preclinical and early-phase clinical studies suggest that intraperitoneal oncolytic viruses can induce immunogenic tumor cell death and T-cell activation, with single-cell analyses indicating remodeling of the ascitic immune microenvironment. Future directions include integrating ascites immune phenotyping, patient-derived organoids for drug sensitivity testing, and machine learning-based decision support to guide personalized immunotherapy.
Related
- Targeting Peripheral T-Cell Lymphomas with Chimeric Antigen Receptor Therapy: Mechanistic Challenges, Clinical Landscape and Future Engineering Perspectives
- Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives.
- Innovative ingredients and sustainable perspectives for future noodle processing
- Barriers and challenges to peer support in chronic kidney disease: a landscape review using thematic synthesis
- Intracranial Hemorrhage in Patients Receiving Factor Xa Inhibitors: Challenges and Perspectives
BibTeX
@article{liu2026emerging,
title = {{Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives}},
author = {Xian Liu and Xiaobo Peng and Xiaoxiao Wu and Yue Wu and Tong Yin and Jingyu Liu and Huawei Xu and Xianbao Zhan},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1893803},
url = {https://europepmc.org/article/PMC/PMC13673327},
note = {CC BY},
}
RIS
TY - JOUR
TI - Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives
AU - Xian Liu
AU - Xiaobo Peng
AU - Xiaoxiao Wu
AU - Yue Wu
AU - Tong Yin
AU - Jingyu Liu
AU - Huawei Xu
AU - Xianbao Zhan
PY - 2026
DA - 2026/10/02
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1893803
UR - https://europepmc.org/article/PMC/PMC13673327
AB - Malignant ascites is a common, severe complication of advanced solid tumors, driven by multifactorial pathogenesis, including impaired lymphatic drainage, vascular endothelial growth factor-induced vascular hyperpermeability, pro-permeability inflammatory cytokines, and profound peritoneal immunosuppression. Clinically, it correlates with poor prognosis, reduced overall survival, and substantial quality-of-life deterioration. Current treatment remains predominantly palliative: repeated large-volume paracentesis offers transient symptom relief, fails to prevent reaccumulation, and carries procedural risks. Emerging evidence indicates malignant ascites is not merely passive fluid accumulation but an active, immunosuppressive niche shaped by bidirectional crosstalk among tumor cells, stromal components, diverse immune subsets (e.g., regulatory T cells, myeloid-derived suppressor cells, dysfunctional CD8 ⁺ T cells), and soluble mediators. This narrative review summarizes recent advances in immunomodulatory treatment for malignant ascites, with an emphasis on strategies targeting the ascitic immune microenvironment. Intraperitoneal administration of immune checkpoint inhibitors has shown acceptable safety and preliminary activity in early-phase single-arm trials, although confirmatory data from larger controlled studies are lacking. In randomized trials, the T-cell engager catumaxomab prolonged puncture-free survival, while the bispecific antibody M701 has shown similar benefits in a phase II randomized controlled study; these findings support further investigation of localized T-cell redirection. Preclinical and early-phase clinical studies suggest that intraperitoneal oncolytic viruses can induce immunogenic tumor cell death and T-cell activation, with single-cell analyses indicating remodeling of the ascitic immune microenvironment. Future directions include integrating ascites immune phenotyping, patient-derived organoids for drug sensitivity testing, and machine learning-based decision support to guide personalized immunotherapy.
SN - 2234-943X
ER -